ACR: CMS rule on Medicare drug price negotiation could have ‘unintended consequences’
The American College of Rheumatology (ACR) warns that a proposed CMS rule on Medicare drug price negotiation may limit access to biologic drugs. The rule could create a 'payment gap' for physician-administered drugs, potentially leading to discontinued use. ACR supports the Protecting Patient Access to Cancer and Complex Therapies Act to address reimbursement issues. Drugs affected include Orencia (BMS), Cosentyx (Novartis), Xeljanz (Pfizer), and Cimzia (UCB).
How this was made
The 30-second read
Why it matters
The rule could create a reimbursement gap, prompting practices to drop certain infusions.
Market read
Regulatory change may affect revenue streams of major pharma firms with Medicare Part B biologics.
What to watch
Potential for new combination drug exemptions could limit the rule's scope.
Background
CMS is proposing a rule to codify Medicare drug price negotiations for Part B biologics.
Ticker impact
CMS rule may reduce reimbursement for Bristol Myers Squibb's Orencia, impacting its revenue.
Downward pressure on BMY stock.
Reimbursement shift from ASP to MFP may lower margins.
Novartis' Cosentyx could face reduced Medicare Part B payments under the new rule.
Potential downside for NVS.
Reimbursement changes could compress margins.
Pfizer's Xeljanz is listed among drugs subject to the negotiation program.
Possible modest decline for PFE.
MFP pricing may not cover acquisition costs.
UCB's Cimzia may see reimbursement gaps under the CMS proposal.
Downside risk for UCB.
Reimbursement shift may affect profitability.
Market effects
Potential pressure on biotech/biopharma companies with Medicare Part B biologics.
U.S. healthcare reimbursement landscape may tighten, affecting rural infusion centers.
May influence global pharma pricing strategies tied to U.S. Medicare.
Counterpoint
If manufacturers absorb the reimbursement gap, stock impact could be muted.
Key entities
- organizationAmerican College of Rheumatology
Advocacy group raising concerns about the rule.
- government agencyCMS
Centers for Medicare & Medicaid Services proposing the rule.
